Roy Buchanan
Stock Analyst at JMP Securities
(4.53)
# 282
Out of 5,006 analysts
71
Total ratings
50.72%
Success rate
38.41%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Market Outperform | $153 → $173 | $96.45 | +79.37% | 8 | Oct 3, 2025 | |
| ASMB Assembly Biosciences | Initiates: Market Outperform | $38 | $24.48 | +55.23% | 1 | Sep 24, 2025 | |
| DVAX Dynavax Technologies | Reiterates: Market Outperform | $32 | $10.14 | +215.58% | 8 | Aug 22, 2025 | |
| ENTA Enanta Pharmaceuticals | Maintains: Market Outperform | $24 → $25 | $11.35 | +120.26% | 15 | Aug 12, 2025 | |
| PYPD PolyPid | Maintains: Market Outperform | $16 → $14 | $3.54 | +295.48% | 2 | Jun 17, 2025 | |
| CVAC CureVac | Reiterates: Market Outperform | $10 | $5.41 | +84.84% | 9 | May 28, 2025 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $5 → $2 | $1.28 | +56.25% | 9 | May 5, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $2.41 | +646.89% | 3 | Mar 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $58.53 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $3.12 | +28.21% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $23 → $14 | $1.48 | +845.95% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $33 | $86.67 | -61.92% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $5 | $4.34 | +15.21% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $787.94 | -43.14% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $11.56 | +38.41% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.85 | - | 2 | Feb 16, 2023 |
Cidara Therapeutics
Oct 3, 2025
Maintains: Market Outperform
Price Target: $153 → $173
Current: $96.45
Upside: +79.37%
Assembly Biosciences
Sep 24, 2025
Initiates: Market Outperform
Price Target: $38
Current: $24.48
Upside: +55.23%
Dynavax Technologies
Aug 22, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $10.14
Upside: +215.58%
Enanta Pharmaceuticals
Aug 12, 2025
Maintains: Market Outperform
Price Target: $24 → $25
Current: $11.35
Upside: +120.26%
PolyPid
Jun 17, 2025
Maintains: Market Outperform
Price Target: $16 → $14
Current: $3.54
Upside: +295.48%
CureVac
May 28, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $5.41
Upside: +84.84%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5 → $2
Current: $1.28
Upside: +56.25%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $2.41
Upside: +646.89%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $58.53
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $3.12
Upside: +28.21%
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $1.48
Upside: +845.95%
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $86.67
Upside: -61.92%
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $4.34
Upside: +15.21%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $787.94
Upside: -43.14%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $11.56
Upside: +38.41%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.85
Upside: -